Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) in Non-Hospitalized COVID-19 Patients
收藏NIAID Data Ecosystem2026-05-01 收录
下载链接：
https://www.ncbi.nlm.nih.gov/sra/SRP464469
下载链接
链接失效反馈官方服务：
资源简介：
As part of the ACTIV-2/A5401 randomized clinical trial (NCT04518410), participants with symptomatic SARS-CoV-2 infection 19 at low risk for progression were randomized 1:1 to subcutaneously administered BMS-986414 (C135-LS) 200 mg plus BMS-986413 (C144-LS) 200 mg (BMS agent) versus placebo. We performed targeted Spike (S) gene next-generation sequencing to detect BMS specific resistance mutations.
创建时间：
2023-10-06
